Menu Fermer

MELY Laurent

Praticien hospitalier

Pédiatre de formation puis spécialisé en pneumologie pédiatrique et mucoviscidose enfant et adulte, j’exerce  actuellement des fonctions de chef de service de maladies respiratoires à l’hôpital Renée Sabran, CHU des Hospices Civils de Lyon avec une orientation pour la mucoviscidose, la réhabilitation respiratoire enfants/adultes et la prise en charge pré et post greffe pulmonaire.

Pour me contacter :

Tél : 04 94 38 17 40
Courriel : laurent.mely@chu-lyon.fr

Principales publications :

  • Burgel PR, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-Gaudelus I, Corvol H, Bui S, Lemonnier L, Dehillotte C, Da Silva J, Paillasseur JL, Hubert D; French Cystic Fibrosis Reference Network Study Group. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. Am J Respir Crit Care Med. 2020 Jan 15;201(2):188-197.
  • Burgel PR, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-Gaudelus I, Corvol H, Bui S, Biouhee T, Hubert D, Munck A, Lemonnier L, Dehillotte C, Silva JD, Paillasseur JL, Martin C; French Cystic Fibrosis Reference Network study group. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. J Cyst Fibros. 2020 Jun 23:S1569-1993(20)30752-9
  • Pineau F, Caimmi D, Magalhães M, Fremy E, Mohamed A, Mely L, Leroy S, Murris M, Claustres M, Chiron R, De Sario A. Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis PLoS One. 2020 Apr 17;15(4)
  • Campredon A, Battistella E, Martin C, Durieu I, Mely L, Marguet C, Belleguic C, Murris-Espin M, Chiron R, Fanton A, Bui S, Reynaud-Gaubert M, Reix P, Hoang-Thi TN, Vakalopoulou M, Revel MP, Da Silva J, Burgel PR, Chassagnon G; French Cystic Fibrosis Reference Network Study Group. Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis. Eur Respir J. 2021 Nov 18:2101344. doi: 10.1183/13993003.01344-2021.
  • Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC.
  • Filleul V, Ladune R, Gruet M, Falzon C, Fuchs A, Mély L, Hayotte M, Vallier JM, Giovannetti P, Ramel S, Vuillemin A, Corrion K, d’Arripe-Longueville F. Development and validation of the Cystic Fibrosis Decisional Balance for Physical Activity scale (CF-DB-PA). BMC Pulm Med. 2021 Apr 14;21(1):121. doi: 10.1186/s12890-021-01471-0.
  • Ladune R, Filleul V, Falzon C, Hayotte M, Mély L, Vallier JM, Gruet M, Vuillemin A, d’Arripe-Longueville F.Perceptions of barriers to and facilitators of physical activity in adults with cystic fibrosis. Physiother Theory Pract. 2021 Nov 30:1-11. doi: 10.1080/09593985.2021.2005201. Online ahead of print.
  • Hubert D, Marguet C, Benichou J, DeSouza C, Payen-Champenois C, Kinnman N, Chandarana K, Munck A, Fajac I; BRIO Study Group. Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization. Pulm Ther. 2021 Dec;7(2):455-468. doi: 10.1007/s41030-021-00158-5. Epub 2021 Jun 8
  • Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Lemonnier L, Burnet E, Paillasseur JL, Da Silva J, Burgel PR. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. J Cyst Fibros. 2022 Feb 2:S1569-1993(22)00032-7. doi: 10.1016/j.jcf.2022.01.012. Online ahead of print.
  • Hebestreit H, Kriemler S, Schindler C, Stein L, Karila C, Urquhart DS, Orenstein DM, Lands LC, Schaeff J, Eber E, Radtke T; ACTIVATE-CF Study Working Group. Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF).Am J Respir Crit Care Med. 2022 Feb 1;205(3):330-339. doi: 10.1164/rccm.202106-1419OC.

Principales expertises :

  • Mucoviscidose et bronchopathies chroniques enfant/adulte
  • Réadaptation respiratoire enfant/adulte (y compris après greffe pulmonaire)